Physician Recruitment of Patients to Non-Therapeutic Oncology Clinical Trials: Ethics Revisited

Tailoring medical treatment to individual patients requires a strong foundation in research to provide the data necessary to understand the relationship between the disease, the patient, and the type of treatment advocated for. Non-therapeutic oncology clinical trials studying therapeutic resistance require the participation of patients, yet only a small percentage enroll. Treating physicians are often relied on to recruit patients, but they have a number of ethical obligations that might be perceived as barriers to recruiting. Concepts such as voluntariness of consent and conflicts of interest can have an impact on whether physicians will discuss clinical trials with their patients and how patients perceive the information. However, these ethical obligations should not be prohibitive to physician recruitment of patients – precautions can be taken to ensure that patients’ consent to research participation is fully voluntary and devoid of conflict, such as the use of other members of the research team than the treating physician to discuss the trial and obtain consent, and better communication between researchers, clinicians, and patients. These can ensure that research benefits are maximized for the good of patients and society.

[1]  H. Ten Have,et al.  The Nuremberg Code. , 2020, Law, medicine & health care : a publication of the American Society of Law & Medicine.

[2]  BP Smith,et al.  Evolving ethics envy—New Zealand sociologists reading the Canadian Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans , 2014 .

[3]  B. Knoppers,et al.  Recruiting Terminally Ill Patients into Non-Therapeutic Oncology Studies: views of Health Professionals , 2012, BMC medical ethics.

[4]  R. Schilsky,et al.  Patient advocates' role in clinical trials , 2012, Cancer.

[5]  R. S. Saver.  Is it Really All about the Money? Reconsidering Non-Financial Interests in Medical Research , 2012, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[6]  Colleen Lewis,et al.  Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials , 2012, Cancer.

[7]  S. Eckstein.  The Oxford Textbook of Clinical Research Ethics , 2012 .

[8]  P. Appelbaum,et al.  Therapeutic misconception in research subjects: Development and validation of a measure , 2012, Clinical trials.

[9]  A. Iafrate,et al.  Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.

[10]  Tatiana G. Kutateladze,et al.  Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[11]  S. Nelson,et al.  Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.

[12]  S. Athar.  Principles of Biomedical Ethics , 2011, The Journal of IMA.

[13]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[14]  N. Keating,et al.  A population-based assessment of specialty physician involvement in cancer clinical trials. , 2011, Journal of the National Cancer Institute.

[15]  R. Wilson.  The Death of Jesse Gelsinger: New Evidence of the Influence of Money and Prestige in Human Research , 2010, American Journal of Law & Medicine.

[16]  R. Schilsky.  Personalized medicine in oncology: the future is now , 2010, Nature Reviews Drug Discovery.

[17]  T. Meuser,et al.  Predictors of Physician Referral for Patient Recruitment to Alzheimer Disease Clinical Trials , 2009, Alzheimer disease and associated disorders.

[18]  James M. Wilson.  Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. , 2009, Molecular genetics and metabolism.

[19]  I. de Melo-Martín,et al.  Beyond informed consent : the therapeutic misconception and trust , 2008 .

[20]  G. Pond,et al.  Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Rosenstein,et al.  The therapeutic orientation to clinical trials. , 2003, The New England journal of medicine.

[22]  C. Gross,et al.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review. , 2003, JAMA.

[23]  Paul S Appelbaum,et al.  The Therapeutic Misconception: Problems and Solutions , 2002, Medical care.

[24]  D. Gandara,et al.  Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[26]  C B Anderson,et al.  A national survey of policies on disclosure of conflicts of interest in biomedical research. , 2000, The New England journal of medicine.

[27]  R. Prescott,et al.  Barriers to participation in randomised controlled trials: a systematic review. , 1999, Journal of clinical epidemiology.

[28]  Nuremberg Military Tribunal.  The Nuremberg Code. , 1996, JAMA.

[29]  N. Kass,et al.  Trust, The fragile foundation of contemporary biomedical research. , 1996, The Hastings Center report.

[30]  M. Ratain,et al.  Perceptions of cancer patients and their physicians involved in phase I trials. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P S Appelbaum,et al.  False hopes and best data: consent to research and the therapeutic misconception. , 1987, The Hastings Center report.

[32]  T. Albrecht,et al.  Oncologists' recommendations of clinical trial participation to patients. , 2008, Patient education and counseling.

[33]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[34]  Heryl,et al.  A NATIONAL SURVEY OF POLICIES ON DISCLOSURE OF CONFLICTS OF INTEREST IN BIOMEDICAL , 2000 .

[35]  P. Weiden,et al.  Perceptions of cancer patients and their physicians involved in phase I clinical trials. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Appelbaum,et al.  The therapeutic misconception: informed consent in psychiatric research. , 1982, International journal of law and psychiatry.